Interaction of Stigmasterol with Trypanosomal Uridylyl Transferase, Farnesyl Diphosphate Synthase and Sterol 14α-demethylase: An In Silico Prediction of Mechanism of Action
-
Published:2019-06-27
Issue:7
Volume:16
Page:799-807
-
ISSN:1570-1808
-
Container-title:Letters in Drug Design & Discovery
-
language:en
-
Short-container-title:LDDD
Author:
Ibrahim Mohammed Auwal1, Isah Murtala Bindawa2, Tajuddeen Nasir3, Hamza Saadatu Auwal3, Mohammed Aminu1
Affiliation:
1. Department of Biochemistry, Ahmadu Bello University, Zaria, Nigeria 2. Department of Biochemistry, Umaru Musa Yar'adua University, Katsina, Nigeria 3. Department of Chemistry, Ahmadu Bello University, Zaria, Nigeria
Abstract
Background:
Trypanosomiasis is one of the neglected tropical diseases and continues to
cause serious morbidity, mortality and economic loss. Current anti-trypanosomal drugs are antiquated
and suffer from a number of serious setbacks, thereby necessitating the search for new
drugs. Stigmasterol has previously demonstrated in vitro and in vivo anti-trypanosomal activity.
Methods:
Herein, stigmasterol was docked into three validated anti-trypanosomal drug targets;
uridylyl transferase, farnesyl diphosphate synthase and sterol 14α-demethylase, in order to elucidate
the possible biochemical targets for the observed anti-trypanosomal activity.
Results:
The binding free energy between stigmasterol and the enzymes was in the order; sterol
14α-demethylase (-8.9 kcal/mol) < uridylyl transferase (-7.9 kcal/mol) < farnesyl diphosphate synthase
(-5.7 kcal/mol). At the lowest energy docked pose, stigmasterol interacts with the active site
of the three trypanosomal enzymes via non-covalent interactions (apart from hydrogen bond) while
highly hydrophobic stigmasterol carbon atoms (21 and 27) were crucial in the interaction with varying
residues of the three anti-trypanosomal targets.
Conclusion:
Therefore, results from this study might suggest that stigmasterol mediated the antitrypanosomal
activity through interaction with the three anti-trypanosomal targets but with more
preference towards sterol 14α-demethylase.
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,Pharmaceutical Science,Molecular Medicine
Reference20 articles.
1. Bhutta ZA, Sommerfeld J, Lassi ZS, Salam RA, Das JK. Global burden, distribution and interventions for the infectious diseases of poverty. 2. Hotez PJ, Alvarado M, Basáñez MG, Bolliger I, Bourne R, Boussinesq M, Brooker SJ, Brown AS, Buckle G, Budke CM, Carabin H, Coffeng LE, Fèvre EM, Fürst T, Halasa YA, Jasrasaria R, Johns NE, Keiser J, King CH, Lozano R, Murdoch ME, O’Hanlon S, Pion SDS, Pullan RL, Ramaiah KD, Roberts T, Shepard DS, Smith JL, Stolk WA, Undurraga EA, Utzinger J, Wang M, Murray CJL, Naghavi M. The global burden of disease study 2010: Interpretation and implications for the neglected tropical diseases. 3. Aksoy S, Weiss BL, Attardo GM. Trypanosome transmission dynamics in tsetse. 4. Torreele E, Bourdin TB, Tweats D, Kaiser M, Brun R, Mazue G, Bray MA, Pecoul B. Fexinidazole-a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. 5. Jacobs RT, Nare B, Wring SA, Orr MD, Chen D, Sligar JM, Jenks MX, Noe RA, Bowling TS, Mercer LT, Rewerts C, Gaukel E, Owens J, Parham R, Randolph R, Beaudet B, Bacchi CJ, Yarlett N, Plattner JJ, Freund Y, Ding C, Akama T, Zhang YK, Brun R, Kaiser M, Scandale I, Don R. Scyx-7158, an orally-active benzoxaborole for the treatment of stage 2 Human African Trypanosomiasis.
|
|